Scholars Central

Research articlePublished 2017

Bupropion Cannot Reduce Acute Kidney Injury Due to Ischemia-Reperfusion

Authors: Guzmán-de la Garza FJ, Cabello-García AJ, Ibarra-Hernandez JM, Martini-Antonio MT, Alarcón-Galván G, Cámara-Lemaroy CR, Vargas-Villarreal J, Hernández SG, Garza JC, Muzquiz-Vidales R, Cordero-Perez P, Garza NEF, Salinas-Martinez AM

Journal of Clinical & Experimental Pharmacology

Volume 7 · Issue 3 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Bupropion can limit the increase of TNF-alpha, reducing the inflammatory response and injury due to Ischemia- Reperfusion (I/R) on tissues such as the bowel. Our objective was to evaluate bupropion as a preconditioning agent for ischemic acute kidney injury. Experiments were performed on female Wistar rats. Bupropion groups received 25 mg/kg 60 min before the maneuver. As a first step, 30 rats with a right nephrectomy were divided into 6 groups (n=5): sham 24, sham 48, bupropion 24, bupropion 48, ischemia-reperfusion 24 and ischemia-reperfusion 48. After 60 min of ischemia (except sham groups) 24 or 48 h of reperfusion was allowed. During a second step, 30 rats, with both kidneys conserved, were divided into 6 groups (n=5): sham 3, sham 72, bupropion 3, bupropion 72, ischemia-reperfusion 3, and ischemia-reperfusion 72 (IR72). Ischemia in these groups (except sham groups) was performed for 60 min only on the left kidney, and 3 or 72 h of reperfusion were allowed. Serum and histologic evaluations were done. After 48 h of reperfusion, all mono-renal rats that received bupropion died. Bupropion cannot avoid histological damage nor does it impact creatinine clearance, BUN, TNF-α or KIM-1 serum levels secondary to I/R. In conclusion: The pharmacologic preconditioning with Bupropion cannot improve the AKI evolution in rats with renal ischemiareperfusion injury.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Pharmacology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pharmacology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Guzmán-de la Garza FJ”
  • BylineArticles whose byline prints “Cabello-García AJ”
  • BylineArticles whose byline prints “Ibarra-Hernandez JM”
  • BylineArticles whose byline prints “Martini-Antonio MT”
  • BylineArticles whose byline prints “Alarcón-Galván G”
  • BylineArticles whose byline prints “Cámara-Lemaroy CR”
  • BylineArticles whose byline prints “Vargas-Villarreal J”
  • BylineArticles whose byline prints “Hernández SG”